Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
(2015) In The Lancet Oncology 16(4). p.447-456- Abstract
- Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. On the basis of the clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, we designed this phase 3 trial to investigate whether vorinostat given as a second-line or third-line therapy improved patients' overall survival.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/5257808
- author
- organization
- publishing date
- 2015
- type
- Contribution to journal
- publication status
- published
- subject
- in
- The Lancet Oncology
- volume
- 16
- issue
- 4
- pages
- 447 - 456
- publisher
- Elsevier
- external identifiers
-
- pmid:25800891
- wos:000352020000051
- scopus:84933526775
- ISSN
- 1474-5488
- DOI
- 10.1016/S1470-2045(15)70056-2
- language
- English
- LU publication?
- yes
- id
- 68518d96-46b7-4406-9f98-24f7eb71bf72 (old id 5257808)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25800891?dopt=Abstract
- date added to LUP
- 2016-04-01 11:06:52
- date last changed
- 2022-04-28 07:15:28
@article{68518d96-46b7-4406-9f98-24f7eb71bf72, abstract = {{Vorinostat is a histone deacetylase inhibitor that changes gene expression and protein activity. On the basis of the clinical benefit reported in patients with malignant pleural mesothelioma treated in a phase 1 study of vorinostat, we designed this phase 3 trial to investigate whether vorinostat given as a second-line or third-line therapy improved patients' overall survival.}}, author = {{Krug, Lee M and Kindler, Hedy L and Calvert, Hilary and Manegold, Christian and Tsao, Anne S and Fennell, Dean and Öhman, Ronny and Plummer, Ruth and Eberhardt, Wilfried E E and Fukuoka, Kazuya and Gaafar, Rabab M and Lafitte, Jean-Jacques and Hillerdal, Gunnar and Chu, Quincy and Buikhuisen, Wieneke A and Lubiniecki, Gregory M and Sun, Xing and Smith, Margaret and Baas, Paul}}, issn = {{1474-5488}}, language = {{eng}}, number = {{4}}, pages = {{447--456}}, publisher = {{Elsevier}}, series = {{The Lancet Oncology}}, title = {{Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.}}, url = {{http://dx.doi.org/10.1016/S1470-2045(15)70056-2}}, doi = {{10.1016/S1470-2045(15)70056-2}}, volume = {{16}}, year = {{2015}}, }